GLPwatch
In overweight or obese adults without diabetes, semaglutide increased weight loss and GI disorders.
Ann Intern Med · 2021
Last updated 2026-05-28In a study of 1,961 overweight or obese adults without diabetes, those taking semaglutide lost an average of 15.3% of their body weight over 68 weeks, compared to 2.6% for those taking a placebo. However, gastrointestinal (GI) disorders like nausea, vomiting, and diarrhea were more common in the semaglutide group (63.5%) than in the placebo group (47.4%).
AI summary of the abstract below.
| Journal | Ann Intern Med, 2021 |
|---|---|
| Citations | 3 |
| Relative citation ratio | 0.25 |
| NIH percentile | 16 |
| Molecules | semaglutide |
| Conditions studied | Obesity |
Abstract
Wilding JPH, Batterham RL, Calanna S, et al. N Engl J Med. 2021;384:989. 33567185.
Verbatim abstract via PubMed 34224258 ↗
Related research
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Once-Weekly Semaglutide in Adults with Overweight or Obesity.
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
- Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
- Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.